



[Welcome to GSK](#)

[Admissions](#)

MEMORIAL HOSPITAL RESEARCH LABORATORIES

# **The Nai-Kong Cheung Lab**

[Cancer Biology](#)


## **Research**

---

[Cancer Engineering](#)

[Research](#)

[Alumni](#)



Nai-Kong V. Cheung, MD, PhD

Enid A. Haupt Chair in Pediatric Oncology, Pediatrics

Professor

---

My lab focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

[View Lab Overview](https://www.sloankettering.edu/research-areas/labs/nai-kong-cheung/overview) (<https://www.sloankettering.edu/research-areas/labs/nai-kong-cheung/overview>)



## Featured News



## At Work: Physician-Scientist Nai-Kong Cheung

Meet pediatric oncologist Nai-Kong Cheung, whose research into solid tumors is creating new hope for children with cancer.

## Publications Highlights

Santich BH, Cheal SM, Ahmed M, McDevitt MR, Yang G, Ouerfelli Q, Veach DR, Fung EK, Patel M, Vargas DB, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK. [A Self-Assembling and DisAssembling \(SADA\) bispecific antibody \(BsAb\) platform for curative 2-step pre-targeted radioimmunotherapy](#) Clin Can Res, 2020;27(2):532-541. doi:10.1158/1078-0432.CCR-20-2150

Gundem G, Levine MF, Roberts SS, Cheung IY, Medina-Martínez JS, Feng Y, Arango-Ossa JE, Chadoutaud L, Rita M, Asimomitis G, Zhou J, You D, Bouvier N, Spitzer B, Solit DB, Dela Cruz F, LaQuaglia MP, Kushner BH, Modak S, Shukla N, Iacobuzio-Donahue CA, Kung AL, Cheung NV, Papaemmanuil E. [Clonal evolution during metastatic spread in high-risk neuroblastoma.](#) Nat Genet. 2023 Jun;55(6):1022-1033. doi: 10.1038/s41588-023-01395-x.

Park JA, Espinosa-Cotton M, Guo HF, Monette S, Cheung NKV. [Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.](#) J Immunother Cancer 2023 Mar;11(3):e006680. doi:10.1136/jitc-2023-006680.


Chung SK, Vargas DB, Chandler CS, Katugampola S, Veach DR, McDevitt MR, Seo SH, Vaughn BA, Rinne SS, Punzalan B, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Yang G, Ouerfelli O, Nash GM, Cerck A, Fung EK, Howell RW, Larson SM, Cheal

SM, Cheung NK. [Efficacy of HER2-Targeted Intraperitoneal 225Ac  \$\alpha\$ -Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis.](#) J Nucl Med. 2023 Sep; 64(9):1439-1445. doi: 10.2967/jnumed.122.265095.

Cheung IY, Mauguen A, Modak S, Ragupathi G, Basu EM, Roberts SS, Kushner BH, Cheung NK. [Effect of Oral  \$\beta\$ -Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial.](#) JAMA Oncol. 2023 Feb;9(2):242-250. doi: 10.1001/jamaoncol.2022.5999

[View All Publications](#)

## People



## Nai-Kong V. Cheung, MD, PhD

*Enid A. Haupt Chair in Pediatric Oncology, Pediatrics*

Professor

- Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.
- MD, PhD (Immunology), Harvard Medical School

[!\[\]\(74d4806277d7e73349d8e8c0897931e9\_img.jpg\) cheungn@mskcc.org](mailto:cheungn@mskcc.org)

Email Address

[!\[\]\(830769b31eeeaca920791081939ff8ba\_img.jpg\) 646-888-2313](tel:646-888-2313)

Office Phone

[!\[\]\(8bba887393ca45b761e5cb49e755e762\_img.jpg\) View physician profile](#)

Physician profile

## Members



Irene Cheung

Laboratory Member and  
Attending Clinical Immunologist



Madelyn Espinosa-Cotton

Senior Research Scientist


Lab  
Alumni

Lab Affiliations

## Open Positions

To learn more about available

postdoctoral opportunities, please visit our [Career Center](#)




To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

## Career Opportunities

**Yi Feng**


Senior Research Assistant

[Apply](#)




**Hong-fen Guo**

Research Assistant/Specialist



**Hoa Tran**


Senior Research Assistant



**Hong Xu**

Senior Research Scientist

[now \(<https://www.sloankettering.edu/research-areas/labs/nai-kong-cheung/career-opportunities>\)](https://www.sloankettering.edu/research-areas/labs/nai-kong-cheung/career-opportunities)



**Qi Chang**


Research Scholar

## Get in Touch

 [cheungn@mskcc.org](mailto:cheungn@mskcc.org)

Lab Head Email

 [646-888-2313](tel:646-888-2313)




Junfang Li  
Research Scholar




Ahmed Mahmoud  
Research Scholar



Navya Vemula  
Postdoctoral Fellow



Yong Wang  
Research Scholar



Sophia Meixuan Zhang  
Research Technician  
financial interests:

- Abpro Inc  
Equity; Intellectual Property Rights
- Biotec Pharmacon  
Intellectual Property Rights
- Eureka Therapeutics Inc

Office Phone

 [646-888-2320](tel:646-888-2320)

Lab Phone

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Nai-Kong V. Cheung discloses the following relationships and

Equity; Professional Services and Activities

- Y-mAbs Therapeutics, Inc.

Equity; Intellectual Property Rights; Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures](#) (<https://www.sloankettering.edu/disclosures>)

© 2025 Louis V. Gerstner Jr. Graduate School of Biomedical Sciences Memorial Sloan Kettering Cancer Center